Robotic Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for Treatment of Gastric Cancer With Limited Peritoneal Metastasis, ROBO-CHIP Study

This phase II clinical trial tests how well robotic cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC) in treating patients with gastric cancer that has spread to the tissue that lines the wall of the abdominal cavity (peritoneum). Gastric cancer is the third leading cause of cancer related deaths worldwide and peritoneal metastasis are found in 30% of patients at time of diagnosis. Patients with peritoneal metastasis have poor survival rates. Traditional surgery is done with a large incision and has a high complication rate and longer hospital stays. Robot assisted (robotic)

Trial Details

NCT ID
NCT05753306
Phase
PHASE2
Sponsor
Mayo Clinic
Status
RECRUITING
Cancer Type
Gastric Cancer
Interventions
  • Cisplatin
  • Computed Tomography
  • Gastrectomy
  • Magnetic Resonance Imaging
  • Positron Emission Tomography
  • Questionnaire Administration
Locations (sample)
  • Rochester, Minnesota, United States|44.02163,-92.4699

Key Eligibility Criteria

  • Restricted to 18 to 80 years of age
  • Eastern Cooperative Oncology Group (ECOG) performance status =\< 2
  • Histologic confirmation of gastric adenocarcinoma including all subtypes and Siewert type II/III gastroesophageal (GE) junction adenocarcinomas
  • Absolute neutrophil count \>= 1,500 / uL

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Gastric Cancer Trials on Trialify →